Proteovant Therapeutics

King of Prussia,

Norwood is currently underway on the build-out of a research and development facility for Proteovant, a newly formed biotech company through investments from Roivant Sciences and SK Inc. Proteovant is focused on discovering and developing transformative medicines to treat patients with life-altering diseases across multiple therapeutic areas through the process of protein degradation.  Acting as design/builder, Norwood is collaborating with our client and the building owner to ensure the timely and cost-effective delivery of the new space, including identifying long-lead items that could otherwise disrupt delivery dates and project budgets.  Once complete, the new space will include 23,000 square feet of office and proprietary labs in an existing flex building. Completion is expected in late summer 2022.

Similar Projects

Science & Technology

Confidential Bio-Pharma Lab

Learn More
Myonex HQ
Science & Technology | Distribution & Manufacturing

Myonex US Headquarters & cGMP Warehouse

Learn More